[Skip to Content]
[Skip to Content Landing]
Article
August 16, 1952

TOPICAL CHLORAMPHENICOL (CHLOROMYCETIN®) THERAPY OF PYOGENIC DERMATOSES

Author Affiliations

(MC) United States Army, Washington, D. C.; Arlington, Va.
From the Dermatology and Syphilology Section, Walter Reed Army Hospital, Lieut. Col. William N. Piper, Medical Corps, Chief of Section (Captain Trice), and the Dermatology and Syphilology Department, Georgetown University Medical School (Dr. Shafer).

JAMA. 1952;149(16):1469-1470. doi:10.1001/jama.1952.72930330010009e
Abstract

The continuing search for more effective agents for the treatment of pyogenic infections of the skin has led to the development of many improved preparations over the past few years.1 In the evaluation of a new agent, two basic factors must be observed. The agent must possess an active bacteriostatic effect, preferably in low concentrations, against a wide spectrum of microorganisms that commonly affect the skin. It must also show a low index of cutaneous sensitivity. Some of the newer antibiotic ointments appear to meet both of these criteria.1 Another factor worthy of consideration is the stability of the preparation in various vehicles. This report evaluates topical chloramphenicol with reference to effectiveness in the treatment of pyodermas, to cutaneous allergenicity, and to applicability in a greaseless base.

HISTORICAL DATA  In 1947, Ehrlich and co-workers2 announced the recovery of a new antibiotic, chloramphenicol (chloromycetin®), from Streptomyces venezuelae

×